Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Blood Borne Virus

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    9 result(s) found for: Blood Borne Virus. Displaying page 1 of 1.
    EudraCT Number: 2007-000440-27 Sponsor Protocol Number: 690701 Start Date*: Information not available in EudraCT
    Sponsor Name:Baxter AG
    Full Title: OPEN-LABEL PHASE IV STUDY TO INVESTIGATE THE SEROPERSISTENCE OF TICK-BORNE ENCEPHALITIS (TBE) VIRUS ANTIBODIES AFTER THE FIRST BOOSTER AND THE RESPONSE TO A SECOND BOOSTER VACCINATION WITH FSME-IMM...
    Medical condition: In this Study the Seropersistence of Tick Borne Encephalitis (TBE) Virus Antibodies after the First Booster and the Response to a Second Booster Vaccination with FSME-IMMUN 0.5ml in Adults will be ...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10043847 Tick-borne viral encephalitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2006-001676-21 Sponsor Protocol Number: V48P7E1 Start Date*: 2006-08-14
    Sponsor Name:Novartis Vaccines and Diagnostics GmbH & Co. KG
    Full Title: A phase IV, open-label, single-center study in adolescents and adults: Evaluation of immunogenicity and safety of the first booster immunization with Chiron’s TBE vaccine for adults in participants...
    Medical condition: TBE prophylaxis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10043847 Tick-borne viral encephalitis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2009-009324-36 Sponsor Protocol Number: B9371021_(Formerly_Baxter_700802) Start Date*: 2009-03-04
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: OPEN-LABEL PHASE IV STUDY TO INVESTIGATE THE SEROPERSISTENCE OF TICK-BORNE ENCEPHALITIS (TBE) VIRUS ANTIBODIES AFTER THE FIRST BOOSTER AND THE RESPONSE TO A SECOND BOOSTER VACCINATION WITH FSME-IMM...
    Medical condition: Active (prophylactic) immunization against TBE The main purpose of this study is to assess the seropersistence of TBE virus antibodies in children, adolescents and young adults who received the fi...
    Disease: Version SOC Term Classification Code Term Level
    18.0 10021881 - Infections and infestations 10043847 Tick-borne viral encephalitis PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2011-002928-41 Sponsor Protocol Number: Immunity_TBE Start Date*: 2013-01-14
    Sponsor Name:Med. Uni. Wien, Klinik für Innere I
    Full Title: Characterization of humoral and cellular immunity for tick-borne encephalitis (TBE) vaccination in allogeneic blood and marrow graft recipients: a pilot study
    Medical condition: Characterization of humoral and cellular immunity for tick-borne encephalitis (TBE) vaccination in allogeneic blood and marrow graft recipients: a pilot study Study group consists of patients 11...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2017-001356-59 Sponsor Protocol Number: 205847 Start Date*: 2017-09-15
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase IV, open-label, single-center study to evaluate long term immunogenicity up to 15 years after the first booster immunization with Encepur Adults (Polygeline-free Tick-borne Encephalitis vac...
    Medical condition: Healthy volunteers (Active immunization in individuals from 12 years of age against tick-borne encephalitis (TBE) virus. The vaccination is intended for residents or travellers in TBE-endemic areas...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2015-004037-26 Sponsor Protocol Number: MV-CHIK-202 Start Date*: 2017-04-11
    Sponsor Name:Themis Bioscience GmbH
    Full Title: Double blinded, randomized, Priorix®- and placebo-controlled, trial to evaluate the optimal dose of MV-CHIK vaccine (against Chikungunya virus) in regard to immunogenicity, safety and tolerability ...
    Medical condition: The MV-CHIK vaccine candidate is developed to prevent infection with the mosquito borne Chikungunya Virus. This Phase 2 trial is designed to investigate the immunogenicity, safety and tolerability ...
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10067256 Chikungunya virus infection PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2005-000768-19 Sponsor Protocol Number: 700501 Start Date*: 2005-08-02
    Sponsor Name:Baxter Vaccine AG
    Full Title: Multicenter Phase IV Study to Investigate the Seropersistence of TBE Virus Antibodies Approximately 3 Years after a Booster Vaccination with FSME-IMMUN 0.25 ml Junior in Children
    Medical condition: Tick-borne encephalitis
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2004-002647-27 Sponsor Protocol Number: 092004 Start Date*: 2005-03-10
    Sponsor Name:Universitätsklinik für Kinder-und Jugendheilkunde
    Full Title: FSME (human tick-borne encephalitis) - vaccination in children after thymectomy
    Medical condition: In children who undergo open heart surgery because of heart vitium, for surgical reasons the thymus has to be removed. If thymectomy in early childhood alters the function of the immunsystem has be...
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2018-000148-24 Sponsor Protocol Number: 1 Start Date*: 2018-06-14
    Sponsor Name:Norwegian University of Science and Technology
    Full Title: Safety and efficacy of plasma transfusion from exercise-trained donors in patients with early Alzheimer’s disease: the ExPlas Study
    Medical condition: Early Alzheimer's disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 23:02:26 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA